RESUMO
OBJECTIVES: Circulating levels of matrix metalloproteinase (MMP)-10 are related to inflammation in asymptomatic subjects with cardiovascular risk factors. Whether MMP-10 is associated with the severity of atherosclerosis remains to be determined. This study examines the relationship of systemic MMP-10 levels with atherosclerotic risk factors and subclinical atherosclerosis. METHODS AND RESULTS: Circulating levels of MMP-1, -9 and -10, and markers of inflammation [fibrinogen, interleukin-6, von Willebrand factor, and high-sensitivity C-reactive protein (hs-CRP)] were measured in 400 subjects (mean age 54.3 years, 77.7% men) with cardiovascular risk factors but free from clinical cardiovascular disease. Subclinical atherosclerosis was evaluated by both the mean carotid intima-media thickness (IMT) and the presence of atherosclerotic plaques with the use of B-mode ultrasound in all subjects. MMP-10 levels were positively correlated with fibrinogen (r = 0.24, P < 0.001), hs-CRP (r = 0.14, P < 0.01) and carotid IMT (r = 0.17, P < 0.01). The association between MMP-10 and IMT remained significant in multiple regression analysis (P < 0.02) when controlling for traditional atherosclerotic risk factors and inflammatory markers. Such an association was not observed for MMP-1 and -9. Subjects in the highest MMP-10 tertile had significantly higher carotid IMT (adjusted odds ratio 6.3, 95% confidence interval 1.3-31.4, P = 0.024). In addition, MMP-10 levels were significantly higher in patients with carotid plaques (n = 78) than in those with no plaques after adjusting for age and sex (P < 0.01). CONCLUSION: Higher serum MMP-10 levels were associated with inflammatory markers, increased carotid IMT and atherosclerotic plaques in asymptomatic subjects. Circulating MMP-10 may be useful to identify subclinical atherosclerosis in subjects free from cardiovascular disease.
Assuntos
Doenças das Artérias Carótidas/diagnóstico por imagem , Doenças das Artérias Carótidas/enzimologia , Artéria Carótida Primitiva/diagnóstico por imagem , Metaloproteinase 10 da Matriz/sangue , Túnica Íntima/diagnóstico por imagem , Túnica Média/diagnóstico por imagem , Proteína C-Reativa/metabolismo , Doenças Cardiovasculares/diagnóstico por imagem , Doenças Cardiovasculares/enzimologia , Doenças das Artérias Carótidas/sangue , Doenças das Artérias Carótidas/etiologia , Feminino , Fibrinogênio/metabolismo , Humanos , Interleucina-6/sangue , Modelos Lineares , Modelos Logísticos , Masculino , Metaloproteinase 1 da Matriz/sangue , Metaloproteinase 9 da Matriz/sangue , Pessoa de Meia-Idade , Razão de Chances , Fatores de Risco , Índice de Gravidade de Doença , Ultrassonografia , Fator de von Willebrand/metabolismoRESUMO
BACKGROUND: Cyclooxygenase (COX)-2, a key regulatory enzyme in prostanoid synthesis, plays an important role in inflammatory processes. The -765G>C COX-2 polymorphism has been associated with lower promoter activity in vitro and reduced levels of C-reactive protein (CRP) in atherosclerotic carriers of the C allele. However, its pathophysiological relevance in vivo has not been fully elucidated. METHODS AND RESULTS: We assessed the -765G>C polymorphism and COX-2 expression in 220 asymptomatic subjects free of cardiovascular disease, in relation to global vascular risk, carotid intima-media thickness (IMT), and inflammatory markers (fibrinogen, C-reactive protein [CRP], von Willebrand factor [vWF] and interleukin-6 [IL-6]). Genotype frequencies were: CC (7.7%), CG (34.5%), GG (57.7%). Among hypercholesterolemic subjects (n=140), C allele carriers had lower COX-2 expression (p<0.05), reduced carotid IMT (p<0.01) and diminished levels of inflammatory markers CRP, vWF and IL-6 (p<0.05), as compared to GG homozygous subjects. The association between carotid IMT and COX-2 polymorphism remained significant after adjusting for cardiovascular risk factors and inflammatory markers (p=0.008). CONCLUSIONS: In asymptomatic hypercholesterolemic subjects the C allele of -765G>C COX-2 polymorphism was associated with lower COX-2 expression, and reduced subclinical atherosclerosis and systemic inflammation compared with GG homozygous, thus conferring atherosclerosis protection in this cardiovascular risk population.
Assuntos
Aterosclerose/diagnóstico , Aterosclerose/genética , Ciclo-Oxigenase 2/genética , Cisteína/genética , Glicina/genética , Polimorfismo Genético/genética , Aterosclerose/classificação , Aterosclerose/enzimologia , Biomarcadores , Colesterol/sangue , Feminino , Regulação Enzimológica da Expressão Gênica , Predisposição Genética para Doença , Humanos , Inflamação , Masculino , Pessoa de Meia-Idade , Monócitos/enzimologiaRESUMO
It is now widely accepted that atherosclerosis is a complex chronic inflammatory disorder of the arterial tree associated with several risk factors. From the initial phases of leukocyte recruitment to eventual rupture of vulnerable atherosclerotic plaques, a low-grade inflammation, also termed microinflammation, appears to play a key pathogenetic role. Experimental and clinical evidence suggests that cyclooxygenase-2 (COX-2), an enzyme which catalyzes the generation of prostaglandins from arachidonic acid, also contributes to lesion formation. COX-2 has been detected in macrophages, smooth muscle cells and endothelial cells in human atherosclerotic lesions. Several studies have also reported the presence of COX-2 in the shoulder region of atherosclerotic plaques, mainly colocalizing with macrophages and MMPs, enzymes that are involved in the destabilization of atherosclerotic plaques, leading to rupture and atherothrombotic syndromes (i.e. acute myocardial infarction). We have recently assessed monocyte COX-2 activity and the production of PGE(2) in a population of apparently healthy subjects free from clinically overt atherosclerosis. We found an association between increased PGE(2) and increasing number of cardiovascular risk factors and carotid intima-media thickness, a noninvasive surrogate marker of atherosclerosis, independently of traditional and non traditional cardiovascular risk factors. Our findings support the notion that the COX-2/PGE(2)axis may have a role in atherosclerosis, and this might be an attractive therapeutic target. COX-2 inhibitors, collectively called coxibs (celecoxib, rofecoxib, valdecoxib, lumiracoxib, etc), held a promise of improved treatment of arthritis without the gastrointestinal side effects associated with aspirin and other nonsteroidal anti-inflammatory drugs. However, clinical studies raise several clinically relevant questions as to their beneficial role in atherosclerosis prevention, because of increased thrombogenicity and cardiovascular risk. Only well designed large scale clinical trials can provide the answer as to the net effect of selective COX-2 inhibition on cardiovascular events before this new class of anti-inflammatory drugs can be incorporated into the armamentarium of atherosclerosis.
Assuntos
Arteriosclerose/tratamento farmacológico , Inibidores de Ciclo-Oxigenase/uso terapêutico , Monócitos/enzimologia , Prostaglandina-Endoperóxido Sintases/sangue , Arteriosclerose/enzimologia , Arteriosclerose/fisiopatologia , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Dinoprostona/metabolismo , Humanos , Proteínas de Membrana , Prostaglandina-Endoperóxido Sintases/fisiologiaRESUMO
Von Willebrand factor (VWF) is considered a reliable marker of endothelial damage. Plasma levels of VWF were measured in 857 middle-aged subjects (80.4% men) free of clinically overt atherosclerotic disease, in relation to cardiovascular risk factors, carotid intima-media thickness (IMT) and microalbuminuria, two established surrogate markers of atherosclerosis. There was linear trend for the increase of VWF, carotid IMT (p < 0.001) and microalbuminuria (p = 0.018). The association between VEF and both markers remained statistically significant after adjusting for cardiovascular risk factors and inflammatory markers (p < 0.01). In conclusion, VWF was independently associated with both structural and functional surrogates of atherosclerosis in asymptomatic subjects, thus representing a systemic biomarker of subclinical atherosclerosis.
Assuntos
Arteriosclerose/sangue , Arteriosclerose/diagnóstico , Fator de von Willebrand/biossíntese , Adulto , Idoso , Albuminúria/metabolismo , Biomarcadores , Testes de Coagulação Sanguínea/métodos , Feminino , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Túnica Íntima/patologia , Túnica Média/patologia , Doenças Vasculares/diagnósticoRESUMO
No disponible
Assuntos
Humanos , Ratos , Animais , Hipertensão/fisiopatologia , Estresse Oxidativo , Espécies Reativas de Oxigênio , Óxido Nítrico/fisiologia , NADPH Oxidases/fisiologia , Ratos Endogâmicos SHR , Aterosclerose/fisiopatologia , Hipertensão/genética , Doenças Cardiovasculares/fisiopatologia , Angiotensina II , Fenótipo , Polimorfismo de Nucleotídeo Único/fisiologiaRESUMO
BACKGROUND: We examined the influence of the 4G/5G PAI-1 (plasminogen activator inhibitor) genotype on Angiotensin II (Ang II)-induced PAI-1 expression by human endothelial cells (HUVEC) in the presence and absence of AT1-receptor blocker losartan, and screened for this polymorphism in relation to plasma PAI-1 and arterial pressure in apparently healthy subjects. METHODS AND RESULTS: Genotyped cultured HUVEC were incubated with Ang II (10(-8) M) with or without losartan up to 24 h. PAI-1 mRNA was determined in cell extracts and protein and activity assessed in supernatants and extracellular matrix (ECM). Ang II increased PAI-1 mRNA and activity in a genotype-dependent manner, higher values observed for 4G/4G HUVEC compared with 4G/5G and 5G/5G genotypes (p<0.05). Laser confocal microscopy and Western blot analysis showed increased PAI-1 protein within ECM in Ang II-stimulated cultures. PAI-1 expression and protein secretion induced by Ang II in 4G/4G HUVEC was completely inhibited by preincubation with 0.05 microM losartan (p<0.01), indicating an AT1-mediated effect. In a group of hypertensives homozygous for the 4G allele, PAI-1 antigen was significantly increased (51.0+/-10.1 ng/ml) compared with normotensives (28.3+/-4.0 ng/ml) and hypertensives carrying the 5G allele (p<0.05). CONCLUSIONS: The 4G/5G PAI-1 polymorphism determines the endothelial PAI-1 upregulation by Ang II and the inhibitory response to losartan. Analysis of PAI-1 genotypes may help identifying subgroups of hypertensives at higher cardiovascular risk.
Assuntos
Angiotensina II/farmacologia , Células Endoteliais/metabolismo , Hipertensão/metabolismo , Inibidor 1 de Ativador de Plasminogênio/genética , Polimorfismo Genético , Análise de Variância , Bloqueadores do Receptor Tipo 1 de Angiotensina II , Estudos de Casos e Controles , Células Cultivadas , Feminino , Fibrinólise , Marcadores Genéticos , Genótipo , Humanos , Losartan/farmacologia , Masculino , Pessoa de Meia-Idade , Inibidor 1 de Ativador de Plasminogênio/imunologia , Inibidor 1 de Ativador de Plasminogênio/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Estatísticas não Paramétricas , Estimulação QuímicaRESUMO
BACKGROUND AND PURPOSE: Thrombin, a central enzyme in the clotting cascade, plays a role not only in thrombosis but also in the progression of atherosclerosis. We studied the relationship between prothrombin fragment 1+2 (F1+2), a specific marker of thrombin generation in vivo, and carotid intima-media thickness (IMT), an index of subclinical atherosclerosis. METHODS: We examined 181 asymptomatic middle-aged subjects (mean age 55.6 years, 76.7% men) free of overt clinical atherosclerotic disease. F1+2 was measured by enzyme-linked immunosorbent assay and IMT by duplex ultrasonography of carotid artery. Multiple linear regression analysis was used to assess the relationship between the 2 parameters. RESULTS: Compared with individuals in the lowest tertile of F1+2, those in the upper tertile (>0.55 nmol/L) showed significantly higher IMT (P<0.01). In correlation analysis, a positive relationship was found between plasma F1+2 and carotid IMT. F1+2 also correlated positively with cholesterol (P<0.008) and low-density lipoprotein cholesterol (P<0.005), but not with blood pressure or body mass index. In the multivariate analysis, the association of F1+2 with carotid IMT remained significant (P<0.001) after adjustment for age, sex, body mass index, systolic blood pressure, cholesterol, diabetes, and smoking. CONCLUSIONS: In a population sample of adults without clinically overt atherosclerotic disease, the plasma levels of F1+2 were significantly associated with carotid IMT, suggesting a relationship between thrombin generation and the development atherosclerosis.
Assuntos
Arteriosclerose , Doenças das Artérias Carótidas/sangue , Doenças das Artérias Carótidas/patologia , Fragmentos de Peptídeos/sangue , Túnica Íntima/patologia , Arteriosclerose/etiologia , Artérias Carótidas/diagnóstico por imagem , Artérias Carótidas/patologia , Doenças das Artérias Carótidas/diagnóstico por imagem , Ensaio de Imunoadsorção Enzimática/estatística & dados numéricos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Protrombina , Análise de Regressão , Fatores de Risco , Túnica Íntima/diagnóstico por imagem , Ultrassonografia Doppler Dupla/estatística & dados numéricosRESUMO
Liver transplant recipients have an increased risk for cardiovascular disease because of a high incidence of obesity, arterial hypertension, diabetes mellitus, and hyperlipidemia. Hyperhomocysteinemia has been found to be an important risk factor for cardiovascular disease in large studies. Fasting serum levels of homocysteine were measured in 105 liver transplant recipients, and hyperhomocysteinemia was defined as a fasting serum homocysteine level greater than 13 micromol/L. Patients with versus without hyperhomocysteinemia were compared. The possible association of hyperhomocysteinemia with age, sex, cause of liver disease, time elapsed since liver transplantation, immunosuppressive therapy, folic acid level, liver function test results, renal function, and other cardiovascular risk factors was investigated. Patients with serum homocysteine levels greater than 15 micromol/L were treated with folic acid, 10 mg/d, and serum homocysteine levels were measured again 1 to 3 months later in 10 patients. Hyperhomocysteinemia was detected in 28 patients (27%). In univariate analysis, it was associated with hepatitis C virus infection, treatment with mycophenolate mofetil, and greater serum levels of alkaline phosphatase, gamma-glutamyl transpeptidase, urea, and creatinine. In multivariate analysis, only greater serum levels of creatinine (P =.006) were associated with hyperhomocysteinemia. Treatment with folic acid resulted in a decrease in fasting serum homocysteine levels in 9 of the 10 patients tested (P =.01). Hyperhomocystinemia, associated with renal dysfunction, is a frequent finding in liver transplant recipients. Treatment with folic acid may reduce fasting homocysteine levels.
Assuntos
Hiper-Homocisteinemia/etiologia , Transplante de Fígado , Complicações Pós-Operatórias , Creatinina/sangue , Feminino , Ácido Fólico/uso terapêutico , Hematínicos/uso terapêutico , Homocisteína/sangue , Humanos , Hiper-Homocisteinemia/sangue , Hiper-Homocisteinemia/tratamento farmacológico , Hiper-Homocisteinemia/epidemiologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Prevalência , Fatores de Risco , Resultado do TratamentoRESUMO
BACKGROUND/AIMS: Oxidative stress could play a role in the pathogenesis of hepatitis C virus infection. We investigated the oxidant/antioxidant status in peripheral blood mononuclear cells from patients with chronic hepatitis C and controls. METHODS/RESULTS: Lipid peroxidation products and superoxide dismutase activity in peripheral blood mononuclear cells were higher in chronic hepatitis C patients than in healthy subjects while glutathione S-transferase activity was reduced in patients as compared to controls. Catalase, glutathione peroxidase and glutathione reductase were similar in chronic hepatitis C and normal individuals. No statistically significant differences were found between patients and controls with regard to glutathione levels in peripheral blood mononuclear cells, but 35% of patients with chronic hepatitis C showed values of glutathione and oxidized glutathione which were below and above, respectively, the limits of normal controls. Finally, the glutathione synthetic capacity of the cytosol of peripheral blood mononuclear cells was significantly higher in patients than in controls, indicating increased glutathione turnover in lymphocytes from patients with chronic hepatitis C. CONCLUSIONS: Oxidative stress is observed in peripheral blood mononuclear cells from chronic hepatitis C patients. This process might alter lymphocyte function and facilitate the chronicity of the infection.
Assuntos
Antioxidantes/metabolismo , Glutationa/sangue , Hepatite C Crônica/sangue , Leucócitos Mononucleares/metabolismo , Adulto , Idoso , Catalase/sangue , Estudos de Coortes , Citosol/metabolismo , Feminino , Glutamato-Cisteína Ligase/sangue , Glutamato-Cisteína Ligase/genética , Glutationa Peroxidase/sangue , Glutationa Redutase/sangue , Humanos , Peroxidação de Lipídeos , Masculino , Malondialdeído/sangue , Pessoa de Meia-Idade , Valores de ReferênciaRESUMO
BACKGROUND: Because the prognosis of patients with hepatocellular carcinoma is not fully understood, particularly regarding therapy, we have evaluated it in a series of patients with a homogeneous diagnostic and therapeutic work-up. METHODS: From 1985 to 1996, 42 variables were recorded prospectively in 178 constructive patients who had a diagnosis of hepatocellular carcinoma. Treatment consisted of liver transplantation ( n = 22), partial hepatectomy (n = 11), arterial, chemoembolization ( n = 52), systemic or regional chemotherapy (n = 51), and other therapies (n = 5); 37 patients received no specific therapy. Statistical analysis was performed according to a Cox model. RESULTS: There were no differences between the survival of patients receiving chemotherapy, other therapies, or no treatment (control group n = 93). survival rates a 1,3, and 5 years were 81%, 74%, and 74% for liver transplantation, 72%, 58%, and 58% for hepatectomy, 55%, 26%, and 13% for chemoembolization, and 13%, 3%, and 0% for the control group. Cirrhosis, systemic syndrome, bilobar involvement, Child's stage C disease, and treatment were independent predictors of survival. CONCLUSIONS: This series shows that certain easily accessible parameters may help establish individual prognosis and stratify patients in clinical trials and indicates that chemoembolization, partial resection, and liver transplantation can prolong life expectancy of patients with hepatocellular carcinoma.
Assuntos
Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/terapia , Quimioembolização Terapêutica , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/terapia , Europa (Continente)/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Prognóstico , Análise de SobrevidaRESUMO
It has been reported that hepatitis C virus (HCV) may cause oxidative stress in infected cells. Patients with chronic hepatitis C exhibit an increased production of tumor necrosis factor-alpha (TNF alpha), a cytokine that can produce oxidative stress by stimulating the generation of reactive oxygen species (ROS). Cell defense against ROS includes overexpression of Mn-superoxide dismutase (SOD), an inducible mitochondrial enzyme. To investigate cell defense against oxidative stress in HCV infection, we analyzed Mn-SOD mRNA in liver and in peripheral blood mononuclear cells (PBMC) from patients with chronic hepatitis C. Mn-SOD expression in PBMC was significantly increased in patients with HCV infection. Patients with sustained virological and biochemical response after therapy showed significantly lower Mn-SOD than patients with positive viremia. By contrast, Mn-SOD expression was not enhanced in the liver of patients with chronic hepatitis C. The values of Mn-SOD mRNA did not correlate with TNF alpha mRNA expression, viral load, or liver disease activity. Our results indicate that in HCV infection an induction of Mn-SOD was present in PBMC but absent in the liver, suggesting that this organ could be less protected against oxidative damage. Oxidative stress could participate in the pathogenesis of HCV infection.
Assuntos
Hepatite C Crônica/enzimologia , Superóxido Dismutase/genética , Adulto , Idoso , Sequência de Bases , Primers do DNA/genética , Feminino , Radicais Livres/metabolismo , Expressão Gênica , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Hepatite C Crônica/sangue , Hepatite C Crônica/genética , Humanos , Leucócitos Mononucleares/enzimologia , Fígado/enzimologia , Masculino , Pessoa de Meia-Idade , Estresse Oxidativo , RNA Mensageiro/sangue , RNA Mensageiro/metabolismo , RNA Viral/sangue , RNA Viral/genética , Fator de Necrose Tumoral alfa/genética , Viremia/sangue , Viremia/enzimologia , Viremia/genéticaRESUMO
Antiphospholipid syndrome is a well-defined clinical and serological entity characterized by arterial and/or venous thrombosis, recurrent abortion and thrombocytopenia. Anticardiolipin antibodies and lupus anticoagulant are autoantibodies directed against negatively charged phospholipids, which represent the serologic criteria for the diagnosis of the antiphospholipid syndrome. In this review the pathogenic mechanisms of anticardiolipin antibodies, their clinical findings and the current therapeutical strategies are discussed.
Assuntos
Síndrome Antifosfolipídica , Doenças Autoimunes , Aborto Habitual/etiologia , Aborto Habitual/prevenção & controle , Animais , Anticorpos Antifosfolipídeos/imunologia , Anticoagulantes/uso terapêutico , Síndrome Antifosfolipídica/diagnóstico , Síndrome Antifosfolipídica/etiologia , Síndrome Antifosfolipídica/imunologia , Síndrome Antifosfolipídica/terapia , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/etiologia , Doenças Autoimunes/imunologia , Doenças Autoimunes/terapia , Transfusão de Componentes Sanguíneos , Doenças do Tecido Conjuntivo/complicações , Feminino , Predisposição Genética para Doença , Glicoproteínas/imunologia , Antígenos HLA-D/genética , Antígenos HLA-D/imunologia , Imunossupressores/uso terapêutico , Infecções/complicações , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos MRL lpr , Mimetismo Molecular , Neoplasias/complicações , Gravidez , Trombocitopenia/tratamento farmacológico , Trombocitopenia/etiologia , Terapia Trombolítica , Trombofilia/tratamento farmacológico , Trombofilia/etiologia , beta 2-Glicoproteína IRESUMO
McArdle's disease (glycogenosis type V) is a metabolic disorder of hydrocarbons, inherited with autosomic recessive pattern. Biochemically is defined by a myophosphorylase deficiency; clinically it is characterized by exercise intolerance, due to the impossibility of providing energetic substrate to the muscle, myalgias and stiffness. We present a case report of a patient with McArdle's disease and we comment the diagnostic procedures and current therapeutic options.
Assuntos
Doença de Depósito de Glicogênio Tipo V/diagnóstico , Fosforilases/deficiência , Adulto , Creatina Quinase/sangue , Proteínas Alimentares/uso terapêutico , Glicogênio/análise , Doença de Depósito de Glicogênio Tipo V/dietoterapia , Doença de Depósito de Glicogênio Tipo V/genética , Doença de Depósito de Glicogênio Tipo V/metabolismo , Glicólise , Humanos , Masculino , Músculo Esquelético/química , Músculo Esquelético/patologia , Mioglobinúria/etiologia , Esforço FísicoRESUMO
Antiphospholipid antibodies are a type of autoantibodies that have been implicated in the occurrence of thrombocytopenia and thrombotic events and have been described in autoimmune disorders and diverse viral diseases. In this study anticardiolipin antibodies (immunoglobulin G [IgG] isotype) were determined in serum from 100 patients with chronic hepatitis C and 52 healthy controls. In addition, hepatitis C virus (HCV) markers (anti-HCV and HCV RNA) were investigated in 73 patients with thrombotic disorders and no clinical evidence of liver disease; of these patients 37 cases tested negatively for anticardiolipin antibodies and 36 positively. Anticardiolipin test was positive more frequently (22%) in the group of patients with chronic hepatitis C than in healthy controls (1.9%; P < .001). Using conditional logistic-regression analysis we found that in hepatitis C patients the presence of thrombocytopenia, portal hypertension and the existence of prior thrombotic episodes were significantly related to positivity for anticardiolipin antibodies (P < .05 in all cases). In patients with no evidence of liver disease and a history of thrombotic events, hepatitis C markers were absent in all cases who tested negatively for anticardiolipin antibodies (n = 37), but were present in 16.7% of those positive for anticardiolipin (n = 36) (P = .01). In conclusion, anticardiolipin antibodies are frequently found in patients with chronic hepatitis C and in these patients they may be implicated in the occurrence of thrombosis and in the development of thrombocytopenia. Occult HCV infection is present in a significant proportion of patients with thrombotic disorders and positive for anticardiolipin (the antiphospholipid syndrome).
Assuntos
Anticorpos Anticardiolipina/sangue , Síndrome Antifosfolipídica/etiologia , Hepatite C/complicações , Hepatite C/imunologia , Adulto , Síndrome Antifosfolipídica/imunologia , Biomarcadores , Doença Crônica , Feminino , Hepatite C/terapia , Humanos , Interferons/uso terapêutico , Masculino , Pessoa de Meia-Idade , Trombose/imunologia , Fatores de TempoAssuntos
Hepatite C/complicações , Adolescente , Adulto , Idoso , Autoanticorpos/análise , Doenças Autoimunes/etiologia , Doenças Autoimunes/imunologia , Criança , Pré-Escolar , Crioglobulinemia/etiologia , Feminino , Glomerulonefrite Membranoproliferativa/etiologia , Hepacivirus/imunologia , Anticorpos Anti-Hepatite C/análise , Humanos , Masculino , Pessoa de Meia-Idade , Porfiria Cutânea Tardia/etiologia , Síndrome de Sjogren/etiologia , Dermatopatias/etiologiaRESUMO
A case of an infected pseudocyst in the head of the pancreas is presented. Due to its small size and fistulization to the duodenum, a drainage catheter was placed through the fistulous tract from a distant transgastric approach. The fistula was balloon dilated to improve its emptying. Sixteen months later the patient remains asymptomatic with no recurrence of the pseudocyst.
Assuntos
Drenagem/métodos , Duodenopatias/etiologia , Duodenopatias/terapia , Fístula Intestinal/etiologia , Fístula Intestinal/terapia , Pseudocisto Pancreático/terapia , Adulto , Cateterismo/métodos , Humanos , Masculino , Pseudocisto Pancreático/complicações , Pseudocisto Pancreático/diagnóstico por imagem , Radiografia , Radiologia Intervencionista/métodosRESUMO
We describe the case of a 51 year-old man affected of relapsing bouts of abdominal pain and hematuria, who began acutely with pain in the right upper quadrant, fever, hematuria, arthralgias and purpura on the lower extremities; ultrasonography revealed the existence of acalculous cholecystitis. The lack of response to intravenous antibiotherapy and the clinical association of cholecystitis to the renal, cutaneous and articular manifestations, oriented to the diagnosis of Schöenlein-Henoch vasculitis; thereafter, the response to steroids was successful and immediate. The etiologic diagnosis of this case of acalculous cholecystitis based on clinical aspects, avoid the surgical therapy and the possible morbidity that this procedure can produce.
Assuntos
Colecistite/etiologia , Vasculite por IgA/complicações , Artralgia/etiologia , Colecistite/diagnóstico por imagem , Colelitíase/diagnóstico , Crioglobulinemia/complicações , Diagnóstico Diferencial , Hematúria/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , UltrassonografiaRESUMO
Neurofibromatosis (Von Recklinghausen's disease) is uninherited as an autosomal dominant trait. It is characterised by the development of tumors in diverse sites, which may be benign or malignant. The case of a 39 year old woman with Von Recklinghausen's disease is discussed. She presented with a 3 year history of episodes of melaena and iron deficient anaemia. Mesenteric angiography demonstrated a hypervascular tumour in the jejunum. It was surgically excised with an anatomopathological diagnosis of neurofibroma.